Presentation is loading. Please wait.

Presentation is loading. Please wait.

Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory.

Published byThomas Todd Modified over 9 years ago

Similar presentations

Presentation on theme: "Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory."— Presentation transcript:

1 Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

2 Kaplan-Meier analysis of time to death in patients prescribed celecoxib, rofecoxib,or non-steroidal anti-inflammatory drugs Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

3 Baseline characteristics of patients with congestive heart failure prescribed celecoxib,rofecoxib,or non-steroidal anti-inflammatory drugs (NSAIDs) Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

4 Prescribing characteristics for patients given celecoxib,rofecoxib,or non-steroidal anti-inflammatory drugs (NSAIDs) Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

5 Kaplan-Meier analysis of time to recurrent congestive heart failure in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

6 Unadjusted rates of study events in patients with congestive heart failure who were prescribed celecoxib,rofecoxib,or non-steroidal anti-inflammatory drugs (NSAIDs) Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

7 Adjusted hazard ratios (95%confidence intervals) for death and recurrent congestive heart failure, combined and alone, according to exposure group Marie Hudson,Hugues Richard,Louise Pilote BMJ 2005;330:1370

8

Download ppt "Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory."

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
UK Renal Registry 16th Annual Report Figure 8.1. Trend in 1 year after 90 day incident patient survival by first modality, 2005–2011 cohort (adjusted to.

UK Renal Registry 16th Annual Report Figure 8.1. Trend in 1 year after 90 day incident patient survival by first modality, 2005–2011 cohort (adjusted to.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:1338- 1347.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting April 12, 2007 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,

Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting April 12, 2007 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
Dose and Time-Dependent Effects of Cyclooxygenase-2 Inhibition on Fracture-Healing by Ann Marie Simon, and J. Patrick O'Connor J Bone Joint Surg Am Volume.

Dose and Time-Dependent Effects of Cyclooxygenase-2 Inhibition on Fracture-Healing by Ann Marie Simon, and J. Patrick O'Connor J Bone Joint Surg Am Volume.
Charlotte Kragelund et al N Engl J Med 2005;352:666- 75 Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.

Charlotte Kragelund et al N Engl J Med 2005;352: Baseline Clinical Characteristics According to Quartiles of NT-pro-BNP.
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:129-139.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.
Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and.

Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.
Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.

Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.
Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Prognosis of Acute Kidney Injury After.

Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Prognosis of Acute Kidney Injury After.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.
Volume 45, Issue 5, Pages (May 2004)

Volume 45, Issue 5, Pages (May 2004)
Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational,

Similar presentations

Ads by Google